Phosphodiesterase Type 5 Inhibition With Tadalafil Changes Outcomes in Heart Failure: Extent of Renal Damage

NCT01960153 · clinicaltrials.gov ↗

PHASE3

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Award was ended by NIH for parent study

Conditions

Heart Failure
Pulmonary Hypertension

Interventions

DRUG: Tadalafil
DRUG: Placebo

Sponsor

Massachusetts General Hospital

Collaborators

[object Object]
[object Object]